Magenta Therapeutics Inc (MGTA)


Stock Price Forecast

Sept. 11, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Magenta Therapeutics Inc chart...

About the Company

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Employees

69

CEO

Jason Gardner

Exchange

NASDAQ

Website

www.magentatx.com

$M

Total Revenue

69

Employees

$78M

Market Capitalization

-1.10

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MGTA News

Dianthus Therapeutics Inc (DNTH)

1y ago, source: Investing

Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Consumer Services, Consumer Goods and Technology sectors led shares lower. At the close in ...

TG Therapeutics Inc TGTX

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

DMAC DiaMedica Therapeutics Inc.

13h ago, source: Seeking Alpha

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company ...

RLAY Relay Therapeutics, Inc.

6d ago, source: Seeking Alpha

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule ...

Adeia Enters into IP License Agreement with Magenta Telekom

16h ago, source:

Adeia Inc. (Nasdaq: ADEA) ("Adeia" or the "Company"), the company whose patented innovations shape the way the world explores and experiences entertainment, today announced Magenta Telekom, a leading ...

Qualigen Therapeutics Inc Ordinary Shares QLGN

2d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner

16d ago, source: Yahoo Finance

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Aldeyra Therapeutics, Inc., a ...

Esperion Therapeutics, Inc. (ESPR)

2d ago, source: Yahoo Finance

and MUNICH, Germany, March 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics, Inc. jointly announced today, that the Committ In ...

Fate Therapeutics, Inc.

12d ago, source: CNN

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...

What's Included In T-Mobile's Magenta Max 55+ Plan (And How It Compares To Others)

5d ago, source: Hosted on MSN

T-Mobile has a selection of plans designed for customers over the age of 55, with the T-Mobile Magenta Max 55+ service ...

Monopar Therapeutics Inc

3mon ago, source: CNN

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development ...

Vivos Therapeutics Inc (VVOS)

1d ago, source: Investing

Vivos Therapeutics, Inc. (VVOS), a medical technology company specializing in the treatment of obstructive sleep apnea (OSA), held its Fourth Quarter and Full Year ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...